"uuid:ID","label","description","instanceType","name","rationale","id"
"c1dc3b7c-3989-4631-acd7-b8eb216d6d09","","The main design for the study","StudyDesign","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
